Drug Repurposing in Anticancer Reagent Development

Author(s): Peng-chen Chen, Xiaolong Liu*, Yao Lin*

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 20 , Issue 5 , 2017

Become EABM
Become Reviewer
Call for Editor


Background: Cancer is a complex disease and a huge threat to human health. The prognosis for some cancer types such as breast cancer has improved dramatically over the past 50 years due to rapid development of surgery, chemotherapy and radiotherapy technologies. However, for many patients bearing unresectable cancers, the prognosis remained poor. For this reason, there is always high demand for newer and better therapeutic reagents in cancer field. But the development of anticancer drugs is risky, lengthy and costly. Not many new anticancer reagents come into market every year.

Objective: This review focuses on the latest progress of chemotherapy drug repurposing in cancer research.

Conclusion: It is clear from the review of that drug repurposing is faster and cheaper than conventional drug development process. The anticancer efficacy of numerous non-cancer drugs are being tested now. However, not many of them have obtained enough evidence to go into clinical trials for cancer treatment. How to filter the right candidate and narrow the gap between bench and bed remains a hurdle for both conventional and repurposing drug development.

Keywords: Drug repurposing, cancer, mechanism, target, signaling pathway, cellular experiments.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 07 September, 2017
Page: [395 - 402]
Pages: 8
DOI: 10.2174/1386207319666161226143424
Price: $65

Article Metrics

PDF: 26
PRC: 2